SCHEMBL9967415

SCHEMBL9967415

CSc1cc(-n2nc(C)cc2Nc2cc(NC(=O)c3cccc(C)c3)ccc2C)ncn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 7/20 0.53
LYN P07948 6/20 0.53
SRC P12931 6/20 0.53
KDR P35968 6/20 0.53
INSR P06213 5/20 0.53
HCK P08631 5/20 0.53
MAPK14 Q16539 2/20 0.42
KCNK3 O14649 2/20 0.42
KCNK9 Q9NPC2 2/20 0.42
KCNH2 Q12809 1/20 0.42
ABL1 P00519 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
BRAF P15056 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADCY8 P40145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9967419 0.90 LCK (0.65) LCKLYNSRCKDRINSR
SCHEMBL3589029 0.89 LCK (0.55) LCKLYNSRCKDRINSR
SCHEMBL9967421 0.88 LCK (0.52) LCKLYNSRCKDRINSR
SCHEMBL9967418 0.87 LCK (0.51) LCKLYNSRCKDRINSR
SCHEMBL9967417 0.87 LCK (0.54) LCKLYNSRCKDRINSR
SCHEMBL9967414 0.83 LCK (0.56) LCKLYNSRCKDRINSR
SCHEMBL9967413 0.83 LCK (0.56) LCKLYNSRCKDRINSR
SCHEMBL9967429 0.82 LCK (0.48) LCKLYNSRCKDRINSR
SCHEMBL9967430 0.81 INSR (0.47) LCKLYNSRCKDRINSR
SCHEMBL9967404 0.81 MAPK14 (0.49) LCKLYNSRCKDRINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK LCK 3/4885LYN 12/4885SRC 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.